Alexander Cumbo
CIK 1685994 · President and CEO · last filed 2026-09-25
Alexander Cumbo is a President and CEO who has filed 47 SEC Form 4 insider transactions across 7 companies since 2017. The most recent filing, for STOK, was dated Sep 25, 2026. Across all open-market trades the lifetime net is −$13.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SRPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 415
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STOK | Director | — | $27.88 | — | $0 | 1 | 2026-09-25 |
| VOR | Director | — | $20.45 | — | $0 | 2 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 3 | 2026-06-08 |
| SLDB | President and CEO | 235,405 | $7.13 | $1.68M | -$1.12M | 12 | 2026-04-21 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 5 | 2025-07-28 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 3 | 2020-04-03 |
| SRPT | EVP, Chief Commercial Officer | 12,008 | $17.78 | $213.5K | -$12.25M | 14 | 2020-02-28 |
Recent Filings
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-25 | STOK | Grant (A) | — | $0 | EDGAR |
| 2026-06-12 | VOR | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-04-21 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2026-02-18 | SLDB | Mixed | +13,387 | -$96.9K | EDGAR |
| 2026-02-18 | SLDB | Notice (144) | −16,644 | -$96.9K | EDGAR |
| 2026-02-06 | SLDB | Sell (S) | −48,913 | -$315.1K | EDGAR |
| 2026-02-04 | SLDB | Notice (144) | −48,913 | -$315.1K | EDGAR |
| 2026-02-02 | SLDB | Mixed | +189,543 | -$516.6K | EDGAR |
| 2026-02-02 | SLDB | Notice (144) | −80,258 | -$516.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.